Zymeworks Inc., of Vancouver, British Columbia, said it entered a research collaboration with the University of Victoria and the BC Cancer Agency to develop engineered cytokine and cytokine receptor pairs. Under the terms, the collaborators will engineer variant forms of cytokine-receptor complexes to allow precise control of cellular signaling events.